(Q33826614)

29 July 2017

1 reference

title

Antisense therapeutics: is it as simple as complementary base recognition? (English)

1 reference

29 July 2017

Agrawal S

1 reference

29 July 2017

Kandimalla ER

series ordinal

1 reference

29 July 2017

publication date

1 February 2000

1 reference

Trends in Molecular Medicine

29 July 2017

published in

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

72-81

1 reference

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Antisense therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Vitravene--another piece in the mosaic

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Keeping the biotechnology of antisense in context.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Antisense oligonucleotide blockade of connexin expression during embryonic bone formation: evidence of functional compensation within a multigene family

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Oligonucleotide sequences required for natural killer cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Effect of different chemically modified oligodeoxynucleotides on immune stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Dual blockade of cyclic AMP response element- (CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide. gene-specific inhibition of tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Selection of single-stranded DNA molecules that bind and inhibit human thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Malaria merozoite surface protein antisense oligodeoxynucleotides lack antisense activity but function as polyanions to inhibit red cell invasion

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Prediction of antisense oligonucleotide efficacy by in vitro methods

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Tetranucleotide GGGA motif in primary RNA transcripts. Novel target site for antisense design

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Single-stranded DNA and RNA targeted triplex-formation: UV, CD and molecular modeling studies of foldback triplexes containing different RNA, 2'-OMe-RNA and DNA strand combinations

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

In VivoPharmacokinetics of Phosphorothioate Oligonucleotides Containing Contiguous Guanosines

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Effects of synthetic oligonucleotides on human complement and coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotides on human complement and coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

On the quality control of antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901638-X

7 January 2021

10.1016/S1357-4310(99)01638-X

Identifiers

DOI

1 reference

29 July 2017

1 reference